| Literature DB >> 28878043 |
Ke Wang1,2, Yi-Qiang Chen3, May M Salido4, Gurjeet S Kohli4, Jin-Liang Kong1, Hong-Jie Liang5, Zi-Ting Yao2, Yan-Tong Xie6, Hua-Yu Wu7, Shuang-Qi Cai1, Daniela I Drautz-Moses4, Aaron E Darling8, Stephan C Schuster4,9, Liang Yang4,9, Yichen Ding10,9,11.
Abstract
Pseudomonas aeruginosa is an opportunistic pathogen that causes severe airway infections in humans. These infections are usually difficult to treat and associated with high mortality rates. While colonizing the human airways, P. aeruginosa could accumulate genetic mutations that often lead to its better adaptability to the host environment. Understanding these evolutionary traits may provide important clues for the development of effective therapies to treat P. aeruginosa infections. In this study, 25 P. aeruginosa isolates were longitudinally sampled from the airways of four ventilator-associated pneumonia (VAP) patients. Pacbio and Illumina sequencing were used to analyse the in vivo evolutionary trajectories of these isolates. Our analysis showed that positive selection dominantly shaped P. aeruginosa genomes during VAP infections and led to three convergent evolution events, including loss-of-function mutations of lasR and mpl, and a pyoverdine-deficient phenotype. Specifically, lasR encodes one of the major transcriptional regulators in quorum sensing, whereas mpl encodes an enzyme responsible for recycling cell wall peptidoglycan. We also found that P. aeruginosa isolated at late stages of VAP infections produce less elastase and are less virulent in vivo than their earlier isolated counterparts, suggesting the short-term in vivo evolution of P. aeruginosa leads to attenuated virulence.Entities:
Keywords: Pseudomonas aeruginosa; adaptation; genomics; in vivo evolution; ventilator-associated pneumonia
Mesh:
Substances:
Year: 2017 PMID: 28878043 PMCID: PMC5627047 DOI: 10.1098/rsob.170029
Source DB: PubMed Journal: Open Biol ISSN: 2046-2441 Impact factor: 6.411
Figure 1.Phylogenetic analysis of the 25 sequenced P. aeruginosa genomes and 30 other P. aeruginosa genomes. The 25 P. aeruginosa isolates sequenced in this study cluster together and form a monophyletic group (asterisk indicates isolate sequenced in this study). Phylogenetic inference was then carried out based on 132 511 variant sites using the approximate maximum-likelihood algorithm, with clade confidence estimated with SH-like support values. Accession numbers of the 30 genomes from GenBank are listed in the electronic supplementary material, table S3.
Figure 2.Sequence conservation between PA_D1 and five other P. aeruginosa genomes. From the innermost to outermost: circle 1, PA_D1, the representative strain in this study; circle 2, NCGM257, a P. aeruginosa strain that causes nosocomial infections in Japan, which is also the closest genome to isolates in this study as shown by the phylogenetic analysis; circle 3, PA14, a highly virulent strain; circle 4, PAO1, the laboratory reference strain; circle 5, DK2, a strain isolated from CF lungs; circle 6, LES431, an endemic strain isolated in UK; circle 7, GIs predicted by IslandViewer 3 [15]; circle 8, antibiotic resistance genes predicted by ResFinder 2.1 server [16].
Antibiotic susceptibility profiles of 25 P. aeruginosa isolates. AMK, amikacin; AMP, ampicillin; ATM, azithromycin; CAZ, ceftazidime; CIP, ciprofloxacin; CRO, ceftriaxone; CTT, cefotetan; CZO, cefazolin; FEP, cefepime; GEM, gentamicin; IMP, imipenem; LVX, levofloxacin; TOB, Tobramycin; TZP, piperacillin-tazobactam. (unit: mg l−1).
| AMK | AMP | ATM | CAZ | CIP | CRO | CTT | CZO | FEP | LVX | GEN | IPM | TOB | TZP | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PA_D1 | 4 | ≥32 | 16 | 4 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | ≤1 | ≥16 | 16 |
| PA_D3 | ≤2 | ≥32 | 16 | 16 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | ≤1 | ≥16 | 64 |
| PA_D8 | ≤2 | ≥32 | 16 | 16 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | ≤1 | ≥16 | 64 |
| PA_D9 | ≤2 | ≥32 | 16 | 16 | ≥4 | ≥64 | ≥64 | ≥64 | 4 | ≥8 | ≥16 | 2 | ≥16 | 32 |
| PA_D2 | 4 | ≥32 | 16 | 16 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | ≤1 | ≥16 | 64 |
| PA_D4 | 16 | ≥32 | 16 | 4 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | ≤1 | ≥16 | 64 |
| PA_D6 | ≤2 | ≥32 | 16 | 8 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | ≤1 | ≥16 | 64 |
| PA_D10 | ≤2 | ≥32 | ≥64 | 16 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | ≤1 | ≥16 | 64 |
| PA_D12 | ≤2 | ≥32 | ≥64 | ≥64 | ≥4 | ≥64 | ≥64 | ≥64 | 16 | ≥8 | ≥16 | 2 | ≥16 | ≥128 |
| PA_D19 | ≤2 | ≥32 | 32 | 4 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | 2 | ≥16 | 64 |
| PA_D21 | 4 | ≥32 | 32 | 32 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | ≤1 | ≥16 | 64 |
| PA_D5 | ≤2 | ≥32 | 16 | 4 | ≥4 | ≥64 | ≥64 | ≥64 | 4 | ≥8 | ≥16 | ≤1 | ≥16 | 16 |
| PA_D7 | ≤2 | ≥32 | 16 | 16 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | ≤1 | ≥16 | 64 |
| PA_D11 | ≤2 | ≥32 | 16 | 8 | ≥4 | ≥64 | ≥64 | ≥64 | 4 | ≥8 | ≥16 | 2 | ≥16 | 64 |
| PA_D13 | ≤2 | ≥32 | 16 | 16 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | 2 | ≥16 | 64 |
| PA_D14 | ≤2 | ≥32 | 16 | 16 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | 2 | ≥16 | 64 |
| PA_D15 | ≤2 | ≥32 | 16 | 16 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | ≤1 | ≥16 | 64 |
| PA_D18 | ≤2 | ≥32 | 16 | 16 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | ≤1 | ≥16 | 64 |
| PA_D22 | ≤2 | ≥32 | 16 | 8 | ≥4 | ≥64 | ≥64 | ≥64 | 8 | ≥8 | ≥16 | 2 | ≥16 | 64 |
| PA_D16 | 4 | ≥32 | ≥64 | ≥64 | ≥4 | ≥64 | ≥64 | ≥64 | ≥64 | ≥8 | ≥16 | ≥16 | ≥16 | ≥128 |
| PA_D17 | 4 | ≥32 | ≥64 | ≥64 | ≥4 | ≥64 | ≥64 | ≥64 | ≥64 | ≥8 | ≥16 | ≥16 | ≥16 | ≥128 |
| PA_D20 | ≤2 | ≥32 | ≥64 | 16 | ≥4 | ≥64 | ≥64 | ≥64 | 32 | ≥8 | ≥16 | ≥16 | ≥16 | 32 |
| PA_D23 | 4 | ≥32 | ≥64 | 16 | ≥4 | ≥64 | ≥64 | ≥64 | 16 | ≥8 | ≥16 | ≥16 | ≥16 | 16 |
| PA_D24 | 4 | ≥32 | ≥64 | 16 | ≥4 | ≥64 | ≥64 | ≥64 | 16 | ≥8 | ≥16 | ≥16 | ≥16 | 16 |
| PA_D25 | ≤2 | ≥32 | ≥64 | 8 | ≥4 | ≥64 | ≥64 | ≥64 | 16 | ≥8 | ≥16 | ≥16 | ≥16 | 16 |
Mutations identified in 25 isolates. SNPs, short indels and gene deletion events are summarized in this table. In each patient, the earliest isolate was chosen as the ancestor for the identification of mutations of the later isolates. For patient 2, the earliest isolate PA_D2 already harbours a non-synonymous mutation in lasR. Therefore, the detection of mutations in lasR for all the isolates from patient 2 were analysed with PA_D1 as the reference. Bold type indicates convergent evolution events in the P. aeruginosa genomes across the four VAP patients.
| isolate | time | coding region change | amino acid change | type | non-synonymous | remarks on |
|---|---|---|---|---|---|---|
| PA_D1 | Day 1 | — | — | — | — | functional |
| PA_D3 | Day 20 | Val261Gly | SNV | yes | functional | |
| PA_D8 | Day 38 | — | — | — | ||
| — | — | — | ||||
| PA_D9 | Day 39 | — | — | — | ||
| — | — | — | ||||
| PA_D2 | Day 1 | Tyr56Cys | SNV | yes | ||
| PA_D4 | Day 14 | — | — | — | ||
| Arg333His | SNV | yes | ||||
| — | SNV | no | ||||
| PA_D6 | Day 25 | Tyr56Cys | SNV | yes | ||
| PA_D10 | Day 29 | Gly99Asp | SNV | yes | functional | |
| — | SNV | no | ||||
| PA_D12 | Day 50 | Arg333His | SNV | yes | functional | |
| Gly97Asp | SNV | yes | ||||
| Gln88* | SNV | yes | ||||
| — | SNV | no | ||||
| PA_D19 | Day 77 | — | — | — | ||
| hypothetical protein, 286C > T | His96Tyr | SNV | yes | |||
| hypothetical protein, 42delC | Pro16fs | deletion | yes | |||
| BarA sensory histidine kinase, | Leu546Pro | SNV | yes | |||
| multimodular transpeptidase-transglycosylase, 1558T > C′ | Ser520Pro | SNV | yes | |||
| — | SNV | no | ||||
| PA_D21 | Day 78 | functional | ||||
| hypothetical protein, 175A > C | Thr59Pro | SNV | yes | |||
| Gly99Asp | SNV | yes | ||||
| — | SNV | no | ||||
| PA_D5 | Day 1 | — | — | — | — | functional |
| PA_D7 | Day 8 | Met38fs | insertion | yes | ||
| Arg216Trp | SNV | yes | ||||
| PA_D11 | Day 27 | Met38fs | insertion | yes | ||
| Arg216Trp | SNV | yes | ||||
| putative lipoprotein, 203A > G | Asp68Gly | SNV | yes | |||
| PA_D13 | Day 36 | Met38fs | insertion | yes | ||
| Arg216Trp | SNV | yes | ||||
| hypothetical protein, 489G > A | Trp163* | SNV | yes | |||
| PA_D14 | Day 43 | Met38fs | insertion | yes | ||
| Arg216Trp | SNV | yes | ||||
| — | SNV | no | ||||
| PA_D15 | Day 50 | Met38fs | insertion | yes | ||
| Arg216Trp | SNV | yes | ||||
| PA_D18 | Day 57 | Met38fs | insertion | yes | ||
| Arg216Trp | SNV | yes | ||||
| PA_D22 | Day 68 | |||||
| PA_D16 | Day 1 | — | — | — | — | functional |
| PA_D17 | Day 2 | — | — | — | — | functional |
| PA_D20 | Day 8 | — | — | — | — | functional |
| PA_D23 | Day 21 | Glu139fs | deletion | yes | ||
| gltJ, 137G > T | Arg46Leu | SNV | yes | |||
| gltJ, 140G > A | Arg47Gln | SNV | yes | |||
| gltJ, 146T > G | Leu49Arg | SNV | yes | |||
| gltJ, 149T > C | Leu50Pro | SNV | yes | |||
| gltJ, 151T > G | Ser51Ala | SNV | yes | |||
| predicted signal transduction protein, 596C > T | Pro199Leu | SNV | yes | |||
| dipeptide-binding ABC transporter, periplasmic substrate-binding component, 1228_1229insACG | Tyr410_Glu411insAsp | Insertion | yes | |||
| PA_D24 | Day 24 | |||||
| PA_D25 | Day 25 | |||||
| Tyr56fs | insertion | yes | ||||
| DNA primase, phage associated, 2006_2007insG | Ala672fs | insertion | yes | |||
| polymyxin resistance protein ArnT, undecaprenyl phosphate-alpha-L-Ara4N transferase; Melittin resistance protein PqaB, 647T > C | Leu216Pro | SNV | yes | |||
| probable sensor/response regulator hybrid, 649G > A | Gly217Arg | SNV | yes | |||
| NADH:ubiquinone oxidoreductase 49 kD subunit 7, 308C > T | Pro103Leu | SNV | yes | |||
| probable conserved membrane protein, 284T > C | Leu95Pro | SNV | yes | |||
| probable iron–sulfur binding protein YPO1417, 213delC | Gly72fs | deletion | yes | |||
| Kynurenine formamidase, 527T > C | Val176Ala | SNV | yes | |||
| AraC family transcriptional regulator, 88C > T | Arg30Cys | SNV | yes | |||
| Ala195Val | SNV | yes | ||||
| Enoyl-CoA hydratase, 466C > T | Pro156Ser | SNV | yes | |||
| 3-deoxy-manno-octulosonate cytidylyltransferase, 8A > G | Gln3Arg | SNV | yes | |||
| Val81Ala | SNV | yes | ||||
| benABC operon transcriptional activator BenR, 866A > G | Asp289Gly | SNV | yes | |||
| hypothetical protein, 176A > G | Asp59Gly | SNV | yes | |||
| Alpha-methylacyl-CoA racemase, 841C > T | Arg281Trp | SNV | yes | |||
| response regulator containing a CheY-like receiver domain and a GGDEF domain, 180G > A | Met60Ile | SNV | yes | |||
| lysine-specific permease, 449G > A | Gly150Asp | SNV | no | |||
| putative translation initiation inhibitor, yjgF family, 184A > G | Ser62Gly | SNV | no | |||
| Tyr56fs | insertion | yes | ||||
| — | SNV | no | ||||
Figure 3.Decreased pyoverdine production by pvdS and NPRS mutants. The four pvdS mutants (PA_D19, PA_D21, PA_D22 and PA_D24) and PA_D25 produced significantly less pyoverdine compared with their ancestor strains, which do not carry any mutations in genes involved in pyoverdine synthesis pathway. Complementation of PA_D19, PA_D21 and PA_D22 with pUCP18::pvdS restored their pyoverdine production to the similar levels as their ancestors. We could not complement the PA_D24 strain with pUCP18::pvdS due to its high resistance to carbenicillin.
Figure 4.Elastase production of the 25 isolates. Isolates from the same patient were lined and plotted against the time of isolation. In patients 1, 3 and 4, the earliest isolates produced high levels of elastase, whereas the latest isolates produced much lower levels. In patient 2, the earliest two isolates low levels of elastase, whereas the three later isolates produced higher levels and eventually the latest two isolates produced the lowest levels of elastase.
Figure 5.The abilities of early and late isolates to cause acute lung infections in a murine pulmonary infection model. Mice were infected with each strain by intranasal inoculation at 106 CFU per mouse. The total bacterial count recovered from the lungs after 24 h of inoculation are shown in the figure. Comparison between CFU recovered from the lungs of mice infected with (a) PA_D1 (ancestor stain from patient 1) and PA_D21 (pvdS mutant from patient 2), (b) PA_D5 (ancestor stain from patient 3) and PA_D22 (lasR/pvdS mutant from patient 3), (c) PA_D16 (ancestor stain from patient 4) and PA_D23 (lasR mutant from patient 4), PA_D24 (lasR/pvdS mutant from patient 4), PA_D25 (lasR/NRPS mutant from patient 4). Solid lines: the median for each group. Dotted lines: the detection limit of CFU counting (n = 6 for PA_D21 and PA_D16, and n = 7 for the other isolates; *p < 0.05, **p < 0.01, ***p < 0.001, n.s. p > 0.05; Mann–Whitney test).